On this page

Recovery has more than one dimension

Recovery depends on the effects of any hemorrhage, pre-existing symptoms, treatment complications and the person's needs. Elimination of an AVM shunt is an anatomical result. It does not demonstrate reversal of earlier brain injury, restored independence, seizure freedom or improved quality of life. Each outcome needs its own assessment.12

After stroke-related injury, physical, occupational and speech/language rehabilitation may help address specific difficulties. Emotional and cognitive problems also deserve assessment and support. Rehabilitation goals should be tailored to the person's situation rather than to a standard recovery deadline. General stroke information can explain these needs, but it cannot predict recovery after a particular AVM treatment.3

Symptoms and seizures need a continuing plan

Seizures can be part of a brain AVM presentation, and an imaging result alone cannot establish that they have resolved. Ask who will coordinate seizure follow-up, how symptoms will be recorded and which changes require prompt contact.42

Sudden severe headache, new weakness, speech or vision disturbance, a first seizure or collapse should receive immediate local medical assessment. Being in recovery or having a reassuring earlier scan does not make new acute symptoms safe to interpret at home.54

Residual lesion and recurrence are different

A residual AVM is shunting or nidus remaining after treatment. After SRS, an AVM can remain present while the intended delayed effect develops; a treatment session is not a declaration of obliteration. After a staged plan, the actual completed stage and remaining lesion must be clear.1

Recurrence describes an AVM detected after previous documented complete obliteration. The method used to confirm that earlier result matters. A statement based on one imaging technique should not be treated as equivalent to every other confirmation method. SNIS recommends imaging follow-up after apparent cure and describes DSA as the reference method for detecting residual or recurrent AVM when findings are concerning.1

Why age matters

Younger patients, especially those presenting with hemorrhage, appear more prone to recurrence in follow-up studies. The Kuopio surgical cohort included both adults and a small pediatric subgroup, with removal initially confirmed by postoperative DSA and variable surveillance across decades. That finding supports a careful follow-up discussion; it does not supply a recurrence probability for every child or adult.6

Adult unruptured ARUBA findings cannot decide pediatric care. Children's development and longer follow-up horizon raise additional questions, and pediatric lesion types must also be distinguished. The follow-up plan should state which age group and confirmation method underlie its evidence.71

Planning the next phase

Ask who is responsible for clinical and imaging follow-up, what findings would prompt reassessment and how results from different specialists will be shared. Imaging should address the actual treatment, remaining anatomy and concerns; there is no universal schedule here. Driving, work, sport, travel and pregnancy discussions require personal assessment and the applicable local rules.

Questions about prognosis or life expectancy are understandable, but published group averages cannot provide a universal survival estimate. Discuss function, symptoms, treatment result and remaining risks as separate topics, along with support for the patient and caregivers. A useful outcome record states the treatment stage, endpoint, confirmation method and duration of follow-up rather than using “cure” to cover every aspect of life afterward.1

References

  1. De Leacy R et al. J NeuroIntervent Surg. 2022;14:1118–1124. doi:10.1136/neurintsurg-2021-018632. Source ↩
  2. Han H, Chen Y, Ma L et al. JAMA Netw Open. 2025;8:e2543408. doi:10.1001/jamanetworkopen.2025.43408. Source ↩
  3. National Institute of Neurological Disorders and Stroke. Stroke Overview and Assess and Treat. Patient information. Source ↩
  4. NHS. Epilepsy. Patient information; reviewed 6 March 2025. Source ↩
  5. US Centers for Disease Control and Prevention. Signs and Symptoms of Stroke. Patient information. Source ↩
  6. Järvelin P et al. Neurosurg Rev. 2023;46:99. doi:10.1007/s10143-023-02001-8. Source ↩
  7. Mohr JP et al. Lancet Neurol. 2020;19:573–581. doi:10.1016/S1474-4422(20)30181-2. PubMed ↩